Abstract: The present invention relates to crystalline forms of mesaconine. Specifically, the present invention relates to crystalline form A, crystalline form B and crystalline form C of mesaconine and preparation methods thereof. In the method, the mesaconine is crystallized in solvent, and then the crude crystal is dried to obtain target crystalline form. The crystalline forms of mesaconine according to the present invention have good solubility, good stability, low hygroscopicity, long-term storage capability and good reproducibility, and have a good prospect to be developed as pharmaceuticals.
Type:
Grant
Filed:
January 23, 2019
Date of Patent:
March 9, 2021
Assignee:
Gooddoctor Pharmaceutical Group Co., Ltd.
Abstract: The present invention relates to a method for preparing mesaconine and related intermediaries. Specifically, in the method for preparing mesaconine of the present invention, aconitine extracted from the Aconitum soongaricum Stapf. of aconitum plant is used as a raw material and subjected to alkalization, acetylation, N-de-ethylation, N-methylation, and hydrolysis to obtain mesaconine. The method for preparing mesaconine in the present invention is simple in operation, high in yield, environmentally friendly and pollution-free, and suitable for industrial production.
Type:
Application
Filed:
January 23, 2019
Publication date:
February 11, 2021
Applicant:
Gooddoctor Pharmaceutical Group Co., Ltd.
Abstract: The present invention relates to crystalline forms of mesaconine. Specifically, the present invention relates to crystalline form A, crystalline form B and crystalline form C of mesaconine and preparation methods thereof. In the method, the mesaconine is crystallized in solvent, and then the crude crystal is dried to obtain target crystalline form. The crystalline forms of mesaconine according to the present invention have good solubility, good stability, low hygroscopicity, long-term storage capability and good reproducibility, and have a good prospect to be developed as pharmaceuticals.
Type:
Application
Filed:
January 23, 2019
Publication date:
October 29, 2020
Applicant:
Gooddoctor Pharmaceutical Group Co., Ltd.
Abstract: The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
February 3, 2015
Assignees:
Sichuan Gooddoctor Pharmaceutical Group Co., Ltd., Si Chuan University
Abstract: The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.
Type:
Application
Filed:
June 15, 2012
Publication date:
May 22, 2014
Applicants:
SI CHUAN UNIVERSITY, SICHUAN GOODDOCTOR PHARMACEUTICAL GROUP CO., LTD